Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 5 (2008), Issue 7 (July)

1. Soluble Nogo-A in CSF is not a useful biomarker for multiple sclerosis.
   Neurology, 71(1): 35-7. [Abstract] [Full-text]
2. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis.
   Neurology, 71(2): 136-44. [Abstract] [Full-text]
3. Temporal trends in the incidence of multiple sclerosis: a systematic review.
   Neurology, 71(2): 129-35. [Abstract] [Full-text]
4. CNS aquaporin-4 autoimmunity in children.
   Neurology, 71(2): 93-100. [Abstract] [Full-text]
5. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.
   J Immunol Methods, 336(2): 113-8. [Abstract] [Full-text]
6. Methylation of class II transactivator gene promoter IV is not associated with susceptibility to multiple sclerosis.
   BMC Med Genet, 9: 63. [Abstract] [Full-text]
7. Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis.
   Arch Neurol, 65(7): 924-8. [Abstract] [Full-text]
8. Optical coherence tomography in neuromyelitis optica.
   Arch Neurol, 65(7): 920-3. [Abstract] [Full-text]
9. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis.
   Arch Neurol, 65(7): 913-9. [Abstract] [Full-text]
10. Role of B:T cell ratio in suppression of clinical signs: a model for silent MS.
    Exp Mol Pathol, 85(1): 28-39. [Abstract] [Full-text]
11. Multiple sclerosis and cannabis: a cognitive and psychiatric study.
    Neurology, 71(3): 164-9. [Abstract] [Full-text]
12. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
    Clin Immunol, 128(2): 219-27. [Abstract] [Full-text]
13. Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease.
    J Neurol Neurosurg Psychiatry, 79(8): 955-8. [Abstract] [Full-text]
14. Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters.
    J Neurol Neurosurg Psychiatry, 79(8): 917-23. [Abstract] [Full-text]
15. Autoantibodies and neurodegeneration in multiple sclerosis.
    Lab Invest, 88(8): 796-807. [Abstract] [Full-text]
16. Quantitative risk-benefit analysis of natalizumab.
    Neurology, 71(5): 357-64. [Abstract] [Full-text]

© 2004-2010 Multiple Sclerosis Research Today. All Rights Reserved.